FDA approves ruxolitinib extended-release tablets for MF, PV, and GVHD
The US Food and Drug Administration (FDA) has approved ruxolitinib (Jakafi XR) extended-release tablets for adults with intermediate or high-risk myelofibrosis and adults
Myeloproliferative Neoplasms
Polycythemia Vera
Primary Myelofibrosis
News
Society Updates
Virtual SOHO Breakthroughs in Blood Cancers meeting returns November 12
In its second year, the Society of Hematologic Oncology (SOHO) will host its virtual SOHO Breakthroughs in Blood Cancers (SBBC) meeting, chaired by
Community Oncology News
Trending now
Community Oncology
News
Dr. Fletcher on barriers to sustaining research outside of academia
Dr. Luke Fletcher leads a discussion at 11:30 am CST on May 15, 2026, on exploration of barriers and solutions for activating and
Leukemia
Acute Myeloid Leukemia
Multiple Myeloma
News
China NMPA accepts IND application for novel bispecific in heme malignancies
The National Medical Products Administration (NMPA) of China accepted the investigational New Drug application for the immunotherapy 6MW5311, a LILRB4/CD3 T-cell engager bispecific
ASH 2025
Lymphoma
Aggressive B-Cell Lymphomas
News
Jean-Marie Michot, MD, discusses the phase 3 Olympia-3 study
The phase 3 trial evaluated the safety and efficacy of odronextamab, a CD20xCD3 bispecific antibody, in combination with CHOP chemotherapy for patients with
Lymphoma
Indolent B-Cell Lymphomas
News
Australia TGA approves tafasitamab combo in relapsed, refractory FL
The phase 3 inMIND trial evaluated the efficacy and safety of tafasitamab in combination with rituximab and lenalidomide in adult patients with relapsed
Leukemia
Acute Myeloid Leukemia
News
Biosimilar filgrastim-laha (FILKRI) receives FDA approval
Accord BioPharma, the therapy's manufacturer, expects a permanent Q-code from the US Centers for Medicare & Medicaid Services.
Ambassador Program
News
Society Updates
SOHO strengthens global leadership in blood cancer research
As we approach the end of the first quarter of 2026, I am pleased to share a brief update on the exceptional successes
SOHO Asia 2026
Leukemia
Acute Myeloid Leukemia
News
Video Interviews
Dr. Feng-Ming Tien on immune landscapes and the future of AML risk stratification
In this video interview from SOHO Asia 2026, Dr. Feng-Ming Tien discusses the critical link between the immune microenvironment and therapeutic success in
Cellular Therapy
Multiple Myeloma
News
Japan’s PMDA clears phase 3 trial of eque-cel in relapsed or refractory MM
The clearance allows the expansion of an international, phase 3 trial (CT103AC004) into Japan. This multi-center study evaluates the efficacy and safety of